PT  - JOURNAL ARTICLE
AU  - Lugang Deng
AU  - Zhi Qu
AU  - Peixi Wang
AU  - Nan Liu
TI  - The Construction and Analysis of ceRNA Network and Immune Infiltration in Kidney Renal Clear Cell Carcinoma
AID  - 10.1101/2021.02.07.21251289
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.07.21251289
4099  - http://medrxiv.org/content/early/2021/02/09/2021.02.07.21251289.short
4100  - http://medrxiv.org/content/early/2021/02/09/2021.02.07.21251289.full
AB  - Background Kidney renal clear cell carcinoma (KIRC) has the highest invasion, mortality and metastasis of the renal cell carcinomas and seriously affects patients’ quality of life. However, the composition of the immune microenvironment and regulatory mechanisms at transcriptomic level such as ceRNA of KIRC are still unclear.Methods We constructed a ceRNA network associated with KIRC by analyzing the long noncoding RNA (lncRNA), miRNA and mRNA expression data of 506 tumor tissue samples and 71 normal adjacent tissue samples downloaded from the Cancer Genome Atlas (TCGA) database. In addition, we estimated the proportion of 22 immune cell types in these samples through “The Cell Type Identification by Estimating Relative Subsets of RNA Transcripts”. Based on the ceRNA network and immune cells screened by univariate Cox analysis and Lasso regression, two nomograms were constructed to predict the prognosis of patients with KIRC. Receiver operating characteristic curves (ROC) and calibration curves were employed to assess the discrimination and accuracy of the nomograms. Consequently, co-expression analysis was carried out to explore the relationship between each prognostic gene in a Cox proportional hazards regression model of ceRNA and each survival-related immune cell in a Cox proportional hazards regression model of immune cell types to reveal the potential regulatory mechanism.Results We established a ceRNA network consisting of 12 lncRNAs, 25 miRNAs and 136 mRNAs. Two nomograms containing seven prognostic genes and two immune cells, respectively, were successfully constructed. Both ROC [Area Under Curves (AUCs) of 1, 3 and 5-year survival in the nomogram based on ceRNA network: 0.779, 0.747 and 0.772; AUCs of 1, 3 and 5-year survivals in nomogram based on immune cells: 0.603, 0.642 and 0.607] and calibration curves indicated good accuracy and clinical application value of both models. Through co-correlation analysis between ceRNA and immune cells, we found both LINC00894 and KIAA1324 were positively correlated with follicular helper T (Tfh) cells and negatively correlated with resting mast cells.Conclusions Based on the ceRNA network and tumor-infiltrating immune cells, we constructed two nomograms to predict the survival of KIRC patients and demonstrated their value in improving the personalized management of KIRC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Natural Science Foundation of China (No. 81872584) and (No. 81472941), National 863 Young Scientist Program (No. 2015AA020940), Key Scientific Research Project Plan of Henan Province (No. 21A330001), Natural Science Foundation of Guangdong Province (No. 2016A030313138), Key Projects of Guangzhou Science and Technology Program (No. 201704020056), Interdisciplinary Research for First-class Discipline Construction Project of Henan University (No. 2019YLXKJC04) and Scientific Research Project for University of Education Bureau of Guangzhou (No. 201831841).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research does not involve animal research and human research, so the necessary IRB and/or ethical review is not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset (TCGA-KIRC) analyzed in this study is publicly available in TCGA (https://tcga-data.nci.nih.gov/tcga/).The other data used to support the findings of this study are available from the corresponding author upon request. https://tcga-data.nci.nih.gov/tcga/